Parkinson’s Disease

Shockat Adam Excerpts

Monday 17th November 2025 Westminster Hall

[Gregory Stafford]

I have also been approached by BeechBand. I hope the Minister agrees that the Medicines and Healthcare products Regulatory Agency and the Government must ensure that where there are new, innovative technologies that could help sufferers of Parkinson’s or any other disease condition, they can get to the frontline to help people as quickly as possible.

[Shockat Adam (Leicester South) (Ind)]

Does the hon. Member agree that early detection is key to fighting this disease? Is he, like me, encouraged by research from Moorfields eye hospital and University College London that found that a scan of the retina—the back of the eye—can detect Parkinson’s disease seven years before any symptoms present?

[Gregory Stafford]

I bow to the hon. Member’s experience on that. I hope the Minister is listening carefully, because these types of innovative technologies can make a significant difference and should be rolled out as quickly as possible.

Living with Parkinson’s brings real financial strain. On average, people spend more than £7,500 each year managing their conditions. That rises to £22,000 when lost earnings are included, so support is not just a clinical need, but an economic one.

In my Farnham and Bordon constituency, which includes Haslemere, Liphook and the surrounding villages, 289 people are currently living with Parkinson’s. The fact that we are—I believe—the only constituency served by three integrated care boards of different sizes brings with it not only challenges but a chance for comparison. Despite their different sizes, some of their challenges are the same, including the increasing number of emergency admissions across all three ICBs. Those numbers lay bare the scale of need and the pressure on services, and underline the urgent requirement for earlier access to specialist care. I raised these concerns in May as the shadow Minister, but I sadly remain unconvinced that the current Government have identified Parkinson’s as a strategic priority.

The new 10-year health plan imagines neighbourhood teams of doctors, nurses, pharmacists, physiotherapists and social workers. It is a positive vision, but it will work only if Parkinson’s specialists are part of those teams. In the Health and Social Care Committee, we often hear about artificial intelligence, remote monitoring and wearable devices, all of which have the potential to transform care through early intervention and better monitoring. The Government must look at those things as well.

I will end with three clear questions. First, in May, the Minister committed to discussing support from the point of diagnosis with Parkinson’s Connect, the Parkinson’s UK programme designed to equip NHS professionals. Have those discussions taken place, and what actions will follow? Secondly, the Minister has said that Parkinson’s nurses are

“worth their weight in gold”—[Official Report, 1 May 2025; Vol. 766, c. 493WH.]

and I agree. What practical measures have been introduced to strengthen training and development for those nurses, particularly those who support patients with the most complex needs?

Thirdly, will the Minister commit to working closely with charities such as Parkinson’s UK to ensure that the 10-year plan gives patients, carers and frontline staff the support they urgently need? Members on both sides of this Chamber share one goal: to get better diagnosis, better treatment and better support for people living with Parkinson’s. Action is what brings progress, and action is what our constituents need and deserve.